alzheimer�*s disease. this is an antibody drug. it binds the protein and stops that protein forming tangles. — with alzheimer�*s. they are often the first warning signs of people with early alzheimer�*s disease. potentially, this could stop that happening. potentially, this could stop that ha enina.~ . potentially, this could stop that happening-— potentially, this could stop that haueninu. . , . , happening. which sounds incredible if it does do — happening. which sounds incredible if it does do that. _ happening. which sounds incredible if it does do that. how— happening. which sounds incredible if it does do that. how is _ happening. which sounds incredible if it does do that. how is your - if it does do that. how is your organisation reacting to this? that organisation reacting to this? git the moment, we can't react until we the moment, we can�*t react until we have a decision. we are waiting for a decision from the american regulator, the fda as to whether they will license this drug in america. we will react when we know what that decision looks like. they will approve it or decline it

extreme drought: the west is drying u up at histotoric ratess farmers s are concererned aboutt their fufuture. alzheimer's drugut: why three doctors who advised the f.d.a. resigned in protest after a new drug was approved. and, talk about burning love-- cbs' steve hartman on how an entire community saved a couple's special day. this is the "cbs evening news" with norah o'donnell, reporting from the nation's capital. >> o'donnell: good evening to our viewers in the west and thank you for joining us. we're going to begin tonight with face-to-face diplomacy back on the global stage. president biden and the g7 allies have wrapped up their first day of meetings, and had dinner hosted by the queen. it began with elbow bumps between president biden and british prime minister boris johnson. the seven world leaders were all smiles as the group posed for the customary family photo, and in a sign of unity, america and its allies are pledging to donate a billion covid vaccine shots for lower income nations. at aecep ron with the royal family, mr. biden became the 13th u.s. president to meet queen elizabeth, and earlier, f

alzheimer's drugs. u.s. regulators give the nod to a controversial therapy, the f.d.a.'s most cons fen -- consequential decision in years. she's very nearly back in the studio she is back in london. annmarie horden, europe reunites from across the pond. good to have you back. i take you to new york, bill dudley, he had hads a warning, i listen to him when he speaks, he ran the new york fed. he said the federal reserve received another recession, why? because the execution of inflation target regular jet stream leaves much to be desired. he's talking about the third leg on the stool, annmarie, not scrust full appointment but running it over, or overheating and therein lies the risk that could be late to the party. good morning, welcome back. dans marie: thanks mark nuss. i'm glad to be back. i have a lot of -- [newline] annmarie: thanks, manus. i'm glad to be back. one thing that i thought was interesting, he said that what the fed is doing, promising to make up for these part misses, when it comes to inflation, is encouraging people to lower inflation expectations. then y

alzheimer's drug; protests intensify as a new pipeline threatens indigenous lands in minnesota; members of the south asian diaspora try to help loved ones amid the covid surge; plus much more. >> woodruff: the f.d.a.'s approval of a new alzheimer's drug today followed months of debate within the medical community about the agency's procedures which, as amna nawaz reports, the announcement has done little to quiet. >> nawaz: that's right, judy. the approval was based on two clinical trials. one showed some improvement in patients who'd been given the drug adcucanumab, but the other found no benefit. a number of practitioners said that was not good enough, and fell short of f.d.a.'s usual standards for approval. and in november, an outside advisory board recommended that f.d.a. not approve the drug. but other medical professionals said the need was so great that any medication that offered promise was worth trying. the last treatment for alzheimer's came on the market some 18 years ago. pam belluck is a health reporter for "the new york times"nd has been following all these developments closely. welcome back to the newshour, thanks for making the time. let's start with the news of the approval today.

january, and the nasdaq composite this week up 1 3/4 percent the biggest s&p winner of the week biogen after its alzheimer druging a downgrade to sell from jpmorgan for its uncertain path to becoming a successful wireless phone provider. dish down more than 11%. caterpillar the biggest laggard on the dow after it boosted its dividend by 8%, cat down 9.5%. all right, 9.5%. if you're an unemployed worker living in alaska, iowa, missouri , or mississippi, pandemic unemployment benefits are getting shut off this weekend. three months earlier than the september expiration date, but even with the labor market recovery gaining traction, it's no question the pandemic has left lasting changes on the workforce, but some sectors are rising above the turmoil and are getting ready to get the job done and your portfolio, to investment strategy analyst ross mayfield, ross great to see you. where are you putting your money these days in this environment? what do you like? >> i like the sectors linked to the economy. we like the cyclical sectors, the value sectors, they've been on quite a run, but based on the last decade, the

s. government health officials have approved the 1st new drug for alzheimer's disease for many 20 years regulate to say the drug which will be marketed as to how is the 1st treatment that target call it this of the disease rather than symptoms. but the approval is controversial with some expert. so arguing that there is no, not enough evidence of real benefits. let's take a closer look, research go to. he's professor of neurology and psychiatry at the mcgill university in montreal. welcome to d. w. professor. where are you on this drug? i do. how is it's a big breakthrough? well, it is an important step forward because it's the 1st mitigation approved for taking out of the brain this build up of the amended protein. and what it is, what is it about that that makes it so significant? well, it's been shown now for a good 10 years that the, it's possible to take out of the brain of persons with early alzheimer at the dementia stage. this excessive build up of middleware. what has been difficult to prove since it's doesn't matter to the patient. and the one of the 2 big studies that lead to

s&p 500 shed 3. >>> the fda approved the first new drug for alzheimer's disease in nearly two decacades, deses fierceerr how i it . the drug c called anduhelelm w created d by buyogegenics. reresearchers say it's the only drug that can treat 6 million americans rather than anxiety and insomnia but some experts say there's not enough to address cognitive symptoms. >>> amazon sidewalk launches with echo devices and in ring cameras. it creates a shared network within neighborhoods and allows devices with spotty wi-fi to stay connected. some security experts say it puts you at risk of being hacked. amazon says it is secure. and your personal information will not be revealed. people do have the choice to opt out. >>> and the boss is coming back to the great white way. bruce springsteen said he'll return to broadway this summer for a limited run of his one-man show where he sings his hit songs and talks about growing up in new jersey. performances will kick off june 26th with an end date sometime in september. springsteen on broadway debuted in 2017 and was extended three times before finally closing in la

s. government health officials have approve the 1st new drug for alzheimer's disease for many 20 years. regulators say that drug which will be marketed as i do hell, is the 1st treatment that targets causes after disease rather than its symptoms. but the approval of controversial with some experts saying there's not enough evidence of real benefits. let's take a closer look, research go to. he's professor of neurology and psychiatry at the mcgill university in montreal. welcome to d. w. professor. where are you on this drug? i do. how is it a big breakthrough? well, it is an important step forward because it's the 1st mitigation approved for taking out of the brain this build up of the amended protein and what it is, what is it about that that makes it so significant? well, it's been shown now for a good 10 years that it's possible to take out of the brain of persons with early alzheimer at the dementia stage. this excessive build up of amino with what has been difficult to prove since it doesn't matter to the patient. and the, one of the 2 big studies that led to this approval showed

still a half percent decline with the dow and the s&p lower nasdaq with a gain biogen soaring thank to the approval for the alzheimer's drug shares up at 408 and still a lot of action in the meme stocks with big gains for amc, gamestop and others on heavy volume ty, also watching apple as the worldwide developers conference is under way this year it is down about 6%, half a percent today. >> all right we'll talk more about that developers conference and why it is different than in prior years but first going to josh lipton for what apple and tim cook have said so far. josh >> apple's developer conference right now and highlights ios 15, that's the new operating system. a lot of new features. facetime upgrades. a new grid view. we know that people that are on facetime a not pandemic and interesting to see what happens as the world normalizes. dau updates to messaging re really rival come petitors all this remember even before this mark zuckerberg did call out apple as a potential rival this is a new look that apple says to help better manage notifications and help them be more efficient order them that sounds small but help

s&p 500 failed to hit a record new high. the nasdaq bucking the negative trend powered by gains in biogen after the fda approved the company's alzheimer's drug. data on the trade deficit and j.o.l.t.s., job listings and number of people quitting their jobs for other positions. >>> salesforce expects half of its employees to work from home even after the pandemic ends. prior to covid, 20% of the staff was working remotely. despite making big investments in real estate including a 61-floor building in san francisco, benihoff suggests the empty space could be used for events or training facilities. >>> the heads of major airlines that fly between the u.s. and great britain are calling on both countries to lift transatlantic travel restrictions put in place during the pandemic. high vaccination rates in the u.s. and uk mean travel could restart safely. the group includes the ceos of american, delta, united, jetblue and british airways. since last march the u.s. barred nearly all non-u.s. citizens who have been in the uk within the past 14 days from entering this country and most u.s. travelers visiting the uk have to quarantine for ten days upon

s. population ages the alzheimers foundation estimates the number of people with alzheimer's will increase 22 percent by 2025 to 7100000. against this grim backdrop by engines new alzheimer's drug add you, can you mab? may be a welcome addition to the small number of drugs used to treat the disease. they will have the opportunity and potential to access something that could change their life. the federal food and drug administration approved the drug on monday. the drug is administered intravenously each month. the patients in the early stages of alzheimer's at you. can you mab is not described as a cure, but it's manufacturer claims it flows. the progression of alzheimer's by removing deposits called amyloid plaques that interfere in brain function in l. summers patients by clearing out this protein, we seem to have sort of a reduction in that progression of the disease. but does it really work? some experts say the evidence is lacking. the manufacturer conducted to randomized trials. one was negative, that is one failed. and one was partially positive, that is the drug appeared to have a modest effect in one group of patients that received it in that 2nd trial. so we're left

giving a boost to the group is biogen this week's biggest gainer on the s&p by far, up almost 44% on the approval of the alzheimer's drugn] [voice of female] my husband ben and i opened ben's chili bowl the very same year that we were married. that's 1958. [voice of male] the chili bowl really has never closed in our history. when the pandemic hit, we had to pivot. and it's been really helpful to keep people updated on google. we wouldn't be here without our wonderful customers. we're really thankful for all of them. [female voices soulfully singing “come on in”] here's your cnbc news update at this hour. the g7 update is getting under way. boris johnson welcomed leaders to cornwall, england he told them it's a meeting that has to happen to learn the lessons of the pandemic so they're not repeated adam schiff is calling for an investigation entowhat he called a terrible abuse of power. "the new york times" is reporting that as part of an effort to find the sources of press leaks, former president trump's justice department secretly issued subpoenas for the email data of some democratic lawmakers, their aides, and even t

s medical editor fergus walsh. this is an historic moment in the battle against alzheimer's. for the first time, a drugproved which tackles not just the symptoms, but the underlying cause of this devastating disease. aducanumab is not yet licenced in the uk and available only as part of a clinical trial, like here, at the national hospital for neurology in central london. aldo, who's 68, was diagnosed with alzheimer's ten years ago and had to stop working as a surgeon. he receives aducanumab every month via infusion and is certain it's helped him. i felt that i wasn't getting so mixed up. my cognitive tests were improving quite markedly. two years ago, aducanumab was written off as a failure and the trial aldo was taking part in was abandoned. but the manufacturers, biogen, analysed more data and concluded those on the highest doses had better cognition, memory and language. this is the brain of someone with early alzheimer's. the red areas show a build—up of amyloid, a protein which can form toxic deposits. this is the same individual after a year of aducanumab. significant amounts of amyloid have bee

s&p up 6 the nasdaq up 20 >>> it's the bottom of the hour. time for the news. the fda says to make a major decision on a new drug to treat alzheimer'sk hanging it up. >>> america reopening more by the day but cruises out of flida remain anchored. >> cruise lines could set sail from the state next month as long as nearly everybody on board proves they are fully vaccinated but in florida, requiring proof is not allowed governor ron desantis signed the law banning vaccine passport it takes effect thfirst of next month the governor will fine cruises for each customer asked to provide proof of vaccination >> we have laws that protect the people and the privacy of our citizens and we are going to enforce it nobody has fought harder not just for cruises but the entire leisure and hospitality sector in this state in its history than me. what cdc has done by closing the cruise industry for over a year, they do not have the authority to do it >> the governor has sued the cdc. requirementss vaccine so far no ruling from the court. nbc shaquille brewster covering the story. >> reporter: for the past 15 months it's been pretty quiet here as the

alzheimer's drug approved yesterday by the fda. the stock higher by 38%. as we head to break, a look at the s&p 500 winners and losers >> announcer: executive edge is sponsored by at&t business our people and network will help keep you connected let's take care of business. yee something different. oh, we can help with that. okay, imagine this... your mover, rob, he's on the scene and needs a plan with a mobile hotspot. we cut to downtown, your sales rep lisa has to send some files, asap! so basically i can pick the right plan for each employee... yeah i should've just led with that... with at&t business... you can pick the best plan for each employee and only pay for the features they need. pain? yeah. here. aspercreme with max-strength* lidocaine. works fast and lasts. keep it. you're gonna need it. kick pain in the aspercreme >>> good morning let's check at the futures things have gotten weaker since we started a half hour ago dow futures are down 150 points. we are looking at the s&p 500. down 11.5. this comes after the s&p had been up about 5 points a swing of 16 points in the last half